Christophe Bourdon

Chief Executive Officer
LEO Pharma A/S

Biography

Christophe Bourdon joined LEO Pharma A/S as CEO in April 2022. In this role, Bourdon has led the company through a significant transformation, substantially growing its topline, improving profitability, and developing a new innovation model to create more effective and user-friendly medicines that address unmet needs in medical dermatology. During the same time, the company achieved multiple product approvals and launches, including in the U.S., EU, and China.

During his 25 years in the pharmaceutical industry across 3 continents, Bourdon’s focus has been to build strong and diverse teams, while fostering an environment focused on innovation and curiosity with one constant driver in mind: Making a meaningful difference for patients.

Prior to joining LEO Pharma, he served as CEO at Orphazyme A/S. Earlier in his career, Bourdon held a series of leadership roles at Amgen, including Senior Vice President and General Manager for the U.S. Oncology Business, with ten marketed portfolios comprising one of the company’s largest businesses. During his tenure in the US, Bourdon helped launching 3 oncology products, managed to launch 2 biosimilars, and accelerated Amgen’s pipeline focus on new innovative cancer medicine.

Earlier, Bourdon was Vice President and General Manager for Amgen, Germany. He also worked at Alexion as Senior Vice President, EMEAC, leading the commercial development of ultra-orphan therapies across 40 countries.

He earned his MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland, and a BA from the Institut Superieur de Gestion/ISG, Paris, France.